Sight Sciences (SGHT) Capital Expenditures (2020 - 2026)

Sight Sciences (SGHT) posted quarterly Capital Expenditures of $60000.0 for Q1 2026, up 126.09% quarter-over-quarter from -$230000.0 in Q4 2025.

Sight Sciences (SGHT) Capital Expenditures (2020 - 2026) Analysis & Trends

Sight Sciences' Capital Expenditures history runs 7 years deep, the most recent figure standing at $60000.0 for Q1 2026.

In Q1 2026, Capital Expenditures changed N/A year-over-year to $60000.0; the TTM figure through Mar 2026 stood at $210000.0 (up 233.33% YoY), while the FY2025 annual figure was $150000.0, up 194.12% from the prior year.
Capital Expenditures for Q1 2026 stood at $60000.0, up from -$230000.0 in the prior quarter.
The five-year high for Capital Expenditures was $807000.0 in Q3 2022, with the low at -$831000.0 in Q4 2022.
The 5-year median for Capital Expenditures is $47500.0 (2022), against an average of $46312.5.
The sharpest annual moves came in 2023 and 2024: Capital Expenditures surged 377.27% in 2023, then sank 857.69% in 2024.
Sight Sciences' Capital Expenditures stood at -$831000.0 in 2022, then soared by 103.13% to $26000.0 in 2023, then tumbled by 857.69% to -$197000.0 in 2024, then declined by 16.75% to -$230000.0 in 2025, then jumped by 126.09% to $60000.0 in 2026.
Business Quant data shows SGHT's Capital Expenditures at $60000.0 in Q1 2026, -$230000.0 in Q4 2025, and $170000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	497.00 Mn
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	202.00 Mn
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	488.00 Mn
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	195.00 Mn
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	66.90 Mn
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	84.70 Mn
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	100.00 Mn
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	-74.39 Mn
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	87.50 Mn
10	Sight Sciences	445.04 Mn	365.29 Mn	21.37 Mn	255,000.00

Download Data